Live
- Mobile subscriptions in India stand at 115.12 crore: Centre
- IIT Kanpur empowers BTech and BS aspirants with new pathways
- South Korean President fails to appear before CIO for questioning over martial law
- HCs cannot lay down the form in which a bail order should be passed by trial courts: SC
- Severe depression threatens AP: Farmers Urged to Take Precautions During Harvest
- Atlee and Vijay Sethupathi's Exciting New Collaboration Announced
- Ponguleti Sudhakar Reddy Criticizes Telangana CM Revanth Reddy’s Rally, Calls It a “Political Gimmick”
- Telangana CM Revanth Reddy Intensifies Attack on Modi, Adani, and BRS Over Alleged Financial Irregularities
- Telangana Congress Leaders Stage Chalo Raj Bhavan Rally Against Manipur and Adani Issues
- BGT: Cummins confirms Hazlewood ruled out of remainder of the series
Dr Reddys Laboratories sets Rs 1,000 crore capex for current fiscal
Dr Reddys Laboratories sets Rs 1,000 crore capex for current fiscal
Hyderabad: The Hyderabad-based drug major Dr Reddy's Laboratories has earmarked a Capex of around Rs 1,000 crore for the current fiscal as it remains...
Hyderabad: The Hyderabad-based drug major Dr Reddy's Laboratories has earmarked a Capex of around Rs 1,000 crore for the current fiscal as it remains positive about sustaining its growth trends in the current fiscal and beyond, as per a top company official. The Hyderabad based firm invested about Rs 1,000 crore in the 2020-21 fiscal.
"The Capex will be around the same numbers, maybe a bit higher if everything goes through," Dr Reddy's Laboratories CEO Erez Israeli said in an analyst call.
However, it depends on the Covid-situation that how much the company would be able to put in during the fiscal, he noted.
He was responding to a query whether the company's Capex for FY22 would be higher than FY21. "We had about give or take a little bit less than Rs 1,000 crore of Capex in FY21," Israeli said.
On the growth outlook for the current fiscal, Israeli noted: "While the current business environment continues to remain uncertain owing to the global pandemic, we believe that the foundation is solid and there are multiple growth levers available for us to sustain growth trends in FY22 and beyond".
The drug maker's growth would be primarily driven by organic moves, focusing around pipeline monetisation, productivity enhancement, diversifications and capability ramp-up in marketing and digitalisation, he added. "Further, our strong balance sheet allows us to continue to invest in the right set of inorganic moves to enable long-term growth," Israeli said.
Dr Reddy's has a net surplus cash of Rs 751 crore as of March 31, 2021, he added.
On the company's North America Generics business, Israeli said that as of March 31, 2021, the drugmaker had 95 cumulative filings pending approval with the US Food and Drug Administration (USFDA), which included 92 abbreviated new drug applications (ANDAs) and three new drug applications (NDAs).
"Overall, in the year (2020-21), we launched 28 new products, including one relaunch. We expect the strong new launches momentum to continue through the current year as well with a similar number of launches," he added.
On a full-year basis (2020-21), the North America Generics business sales stood at USD 948 million, a growth of 4 per cent over the previous year (2019-20). The overall revenues of the drugmaker for FY21 stood at Rs 18,972 crore.
